ALLMedicine™ Pediatric Neuroblastoma Center

Feb 25th, 2023 - To construct and validate a combined model based on axial skeleton radiomics of 18F-FDG PET/CT for predicting event-free survival in high-risk pediatric neuroblastoma patients. Eighty-seven high-risk neuroblastoma patients were retrospectively enr...

Jan 27th, 2023 - Part 1: Dose escalation and expansion of APG-115 monotherapy in pediatric neuroblastoma or solid tumors to determine MTD and recommended phase 2 dose, RP2D. Part 2: Dose escalation of APG-2575 to determine the MTD and RP2D combined with APG-115 at...

Jan 23rd, 2023 - Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to hi...

Nov 21st, 2022 - The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Nov 8th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

Jan 27th, 2023 - Part 1: Dose escalation and expansion of APG-115 monotherapy in pediatric neuroblastoma or solid tumors to determine MTD and recommended phase 2 dose, RP2D. Part 2: Dose escalation of APG-2575 to determine the MTD and RP2D combined with APG-115 at...

Nov 21st, 2022 - The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Nov 8th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

Aug 31st, 2021 - The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.

May 4th, 2018 - One of the challenges of the practical application of immunotherapy for brain tumors is the lack of expression of tumor antigens as well as the down-regulation of Major Histocompatibility Complex (MHC Class I and II ) molecules, which are needed f...

Oct 31st, 2022 - Y-mAbs Therapeutics has suffered a setback in its efforts to win US approval for I-omburtamab to treat a rare pediatric cancer. On October 28, a Food and Drug Administration (FDA) advisory panel found a lack of evidence to support the drug's appro...

May 26th, 2022 - Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival (OS) rates compared with other children, according to an analysis of data from Children’s Oncology Group...

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...